Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a severe mental illness with a biological basis. However, the search for reliable biomarkers suitable for clinical routine has been futile so far. Accordingly, there is a need for innovative approaches such as genomics and proteomics to achieve this goal. In the present study, we compared metabolomic and proteomic data from 26 schizophrenia patients as well as from unaffected controls carefully matched for age and gender in a multi-platform approach. The combined analysis identified many signatures with initially good biomarker characteristics. After statistical analysis and comparison of these identified serum metabolites (analysed by Gas Chromatography Mass Spectrometry) and hydrophobic serum proteins (analysed by matrix-assisted laser desorption ionisation mass spectrometry), several markers (e.g., 2-piperidinec carboxylic acid, 6-deoxy-mannofuranose, galactoseoxime and a serum peptide of m/z 3177) were determined as having the best discriminating value between the groups. Our findings represent a proof of principle indicating that metabolomic and proteomic approaches can be successfully used in psychiatric biomarker research, even though the results should be regarded as preliminary with a need for replication in larger samples.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Proteomics approach has been widely adopted in studies of human diseases including cancer (Frantzi et al., 2015; S. Pan, Brentnall, & Chen, 2015; Petricoin et al., 2002; Tsai et al., 2015), multiple sclerosis (Farias, Pradella, Schmitt, Santos, & Martins-de-Souza, 2014) and schizophrenia (Al Awam et al., 2015; Nascimento & Martins-de-Souza, 2015).”
From Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases (2016) · cites this paper as Al Awam et al., 2015
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
The environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572
Mueser, K. T., & McGurk, S. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16458-1 · Cited by 876
Statistical Evaluation of a Biomarker
Ray, P., Manach, Y. L., Riou, B., Houle, T. T., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181d47604 · Cited by 503
Domenici, E., Willé, D. R., Tozzi, F., Prokopenko, I., Miller, S., McKeown, A., Brittain, C., Rujescu, D., Giegling, I., Turck, C. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009166 · Cited by 347
GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia
Gonzalez-Burgos, G., Fish, K. N., & Lewis, D. A. (2011) · Neural Plasticity · doi:10.1155/2011/723184 · Cited by 246
Schizophrenia shows a unique metabolomics signature in plasma
He, Y., Yu, Z., Giegling, I., Xie, L., Hartmann, A. M., Prehn, C., Adamski, J., Kahn, R., Li, Y., Illig, T., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.76 · Cited by 171
Orešič, M., Seppänen‐Laakso, T., Sun, D., Tang, J. P., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. M., et al. (2012) · eScholarship (California Digital Library) · Cited by 168
Xuan, J., Pan, G., Qiu, Y., Yang, L., Su, M., Liu, Y., Chen, J., Feng, G., Fang, Y., Jia, W., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr2006796 · Cited by 159
Metabolome in schizophrenia and other psychotic disorders: a general population-based study
Orešič, M., Tang, J., Seppänen-Laakso, T., Mattila, I., Saarni, S. E., Saarni, S. I., Lönnqvist, J., Sysi-Aho, M., Hyötyläinen, T., Perälä, J., et al. (2011) · Genome Medicine · doi:10.1186/gm233 · Cited by 157
Multiple Hypothesis Testing in Proteomics: A Strategy for Experimental Work
Diz, A. P., Carvajal-Rodríguez, A., & Skibinski, D. O. F. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.004374 · Cited by 157
In Vivo Measurements of Glutamate, GABA, and NAAG in Schizophrenia
Rowland, L. M., Kontson, K., West, J., Edden, R. A., Zhu, H., Wijtenburg, S. A., Holcomb, H. H., & Barker, P. B. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs092 · Cited by 151
Budczies, J., Denkert, C., Müller, B. M., Brockmöller, S. F., Klauschen, F., Györffy, B., Dietel, M., Richter-Ehrenstein, C., Marten, U., Salek, R. M., et al. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-334 · Cited by 150
Huang, J. T.-J., Wang, L., Prabakaran, S., Wengenroth, M., Lockstone, H. E., Koethe, D., Gerth, C. W., Gross, S., Schreiber, D., Lilley, K. S., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002108 · Cited by 133
Global proteomic profiling reveals altered proteomic signature in schizophrenia serum
Levin, Y., Wang, L., Schwarz, E., Koethe, D., Leweke, F. M., & Bahn, S. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.54 · Cited by 115
Potential biomarkers in psychiatry: focus on the cholesterol system
Woods, A. G., Sokolowska, I., Taurines, R., Gerlach, M., Dudley, E., Thome, J., & Darie, C. C. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01543.x · Cited by 105
Self-citationProteomic research in psychiatry
Taurines, R., Dudley, E., Grassl, J., Warnke, A., Gerlach, M., Coogan, A. N., & Thome, J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106931 · Cited by 92
Self-citationProtein phosphorylation patterns in serum from schizophrenia patients and healthy controls
Jaros, J. A. J., Martins‐de‐Souza, D., Rahmoune, H., Rothermundt, M., Leweke, F. M., Guest, P. C., & Bahn, S. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.05.027 · Cited by 90
Stoeber, G., Ben‐Shachar, D., Cardon, M., Falkai, P., Fonteh, A. N., Gawlik, M., Glenthoj, B. Y., Grünblatt, E., Jablensky, A. V., Kim, Y., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902898980 · Cited by 87
Self-citationBioactive lipids in schizophrenia
Berger, G. E., Smesny, S., & Amminger, G. P. (2006) · International Review of Psychiatry · doi:10.1080/09540260600583072 · Cited by 79
Schmidt‐Glenewinkel, T., Nomura, Y., & Giacobini, E. (1977) · Neurochemical Research · doi:10.1007/bf00963776 · Cited by 68
Estrada, R., & Yappert, M. C. (2004) · Journal of Mass Spectrometry · doi:10.1002/jms.759 · Cited by 64
Altered Cortical GABA Neurotransmission in Schizophrenia: Insights into Novel Therapeutic Strategies
D. Stan, A., & A. Lewis, D. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784925 · Cited by 61
Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia
Bičíková, M., Hill, M., Řípová, D., Mohr, P., & Hampl, R. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.08.009 · Cited by 60
KRAKOWSKI, M. I., & Czobor, P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.005 · Cited by 59
Guti�rrez, M. C., & Delgado‐Coello, B. (1989) · Neurochemical Research · doi:10.1007/bf00964852 · Cited by 57
Martins‐de‐Souza, D., Wobrock, T., Zerr, I., Schmitt, A., Gawinecka, J., Schneider-Axmann, T., Falkai, P., & Turck, C. W. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622971003758748 · Cited by 57
Taurines, R., Dudley, E., Conner, A. C., Grassl, J., Jans, T., Guderian, F., Mehler‐Wex, C., Warnke, A., Gerlach, M., & Thome, J. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0066-5 · Cited by 57
Self-citationDecreased levels of apolipoprotein A-I in plasma of schizophrenic patients
La, Y., Wan, C., Zhu, H., Yang, Y., Chen, Y. S., Pan, Y. X., Feng, G., & He, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0607-2 · Cited by 40
A well‐characterised peak identification list of MALDI MS profile peaks for human blood serum
Tiss, A., Smith, C., Menon, U., et al. (2010) · PROTEOMICS · doi:10.1002/pmic.201000100 · Cited by 35
Roser, M., Josić, D., Kontou, M., Mosetter, K., Maurer, P., & Reutter, W. G. (2008) · Journal of Neural Transmission · doi:10.1007/s00702-008-0166-9 · Cited by 34
Vila‐Rodriguez, F., Honer, W. G., Innis, S. M., Wellington, C. L., & Beasley, C. L. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.090116 · Cited by 24
Profiling for novel proteomics biomarkers in neurodevelopmental disorders
Dudley, E., Häßler, F., & Thome, J. (2011) · Expert Review of Proteomics · doi:10.1586/epr.10.97 · Cited by 23
Self-citationNishio, H., & Giacobini, E. (1981) · Neurochemical Research · doi:10.1007/bf00965042 · Cited by 22
Protein and peptide profiling as a tool for biomarker discovery in depression
Alawam, K., Dudley, E., Donev, R., & Thome, J. (2012) · Electrophoresis · doi:10.1002/elps.201200248 · Cited by 20
Self-citationAlterations of primary fatty acid amides in serum of patients with severe mental illness
Bahn, S. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e246 · Cited by 18
A roadmap to disentangle the molecular etiology of schizophrenia
Falkai, P., Mike, O., Myin‐Germeys, I., Harrison, P. J., Bilkei‐Gorzó, A., & Frangou, S. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.02.006 · Cited by 7
Orešič, M., Seppänen-Laakso, T., Sun, D., Tang, J., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P., et al. (2012) · Genome Medicine · doi:10.1186/gm300 · Cited by 5
Meister, L., Alawam, K., Dudley, E., Taurines, R., Müller, S., Walter, M., Höppner, J., Teipel, S. J., Donev, R., Eckert, A., et al. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.598712 · Cited by 3
Self-citation
Cited by
Sun, Y. V., & Hu, Y.-J. (2016) · Advances in Genetics · doi:10.1016/bs.adgen.2015.11.004 · Cited by 459
“…of human diseases including cancer (Frantzi et al., 2015; S. Pan, Brentnall, & Chen, 2015; Petricoin et al., 2002; Tsai et al., 2015), multiple sclerosis (Farias, Pradella, Schmitt, Santos, & Martins-de-Souza, 2014) and schizophrenia (Al Awam et al., 2015; Nascimento & Martins-de-Souza, 2015).”
Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia
Quintero, M., Stanisic, D., Cruz, G., Pontes, J. G. M., Costa, T. B. B. C., & Tasic, L. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_14 · Cited by 32
Metadata
- Authors
- Al Awam, K., Haußleiter, I. S., Dudley, E., Donev, R., Brüne, M., Juckel, G., & Thome, J.
- Affiliations
- LWL-Universitätsklinikum Bochum (DE)
- Swansea University (GB)
- Corresponding author
- Dudley, Ed
- Venue
- Journal of Neural Transmission
- Published
- 2014-05-01
- Volume
- 122
- Issue
- S1
- Pages
- 111-122
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2129624436
- Cited by
- 42
- References
- 41
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 7 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 3
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- schizophrenia, serum biomarkers, serum metabolites, serum proteins, metabolomics, proteomics, diagnostic signature
- MeSH terms
- Adult, Aged, Blood Proteins, Female, Humans, Lipids, Male, Middle Aged, ROC Curve, Schizophrenia, Cohort Studies, Case-Control Studies, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Proteome, Proteomics, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.